| 2025-11-13 |
详情>>
股本变动：
变动后总股本19232.40万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.16美元,归母净利润-2974.5万美元,同比去年增长48.17%
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-0.12美元,归母净利润-2200.3万美元,同比去年增长41.59%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.13美元,归母净利润-2452.6万美元,同比去年增长-37.21%
|
| 2025-04-04 |
股东大会：
将于2025-05-21召开股东大会
会议内容 ▼▲
- 1.To elect the five director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Management Proxy Circular and Proxy Statement (commonly referred to as a “Say on Pay” vote);
3.To approve the appointment of Ernst & Young LLP (“EY”) as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To transact such other business as may properly come before the Annual Meeting, or at any adjournments or postponements thereof.
|
| 2025-03-27 |
详情>>
业绩披露：
2024年年报每股收益-0.38美元,归母净利润-6992万美元,同比去年增长4.02%
|
| 2025-02-14 |
详情>>
内部人交易：
HASTINGS DAVID C等共交易4笔
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.31美元,归母净利润-5738.8万美元,同比去年增长-7.19%
|
| 2024-11-06 |
财报披露：
美东时间 2024-11-06 盘前发布财报
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.21美元,归母净利润-3767.1万美元,同比去年增长-12.68%
|
| 2024-08-01 |
复牌提示：
2024-08-01 07:25:00 停牌，复牌日期 2024-08-01 08:00:00
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.1美元,归母净利润-1787.5万美元,同比去年增长-9.4%
|
| 2024-04-10 |
股东大会：
将于2024-05-22召开股东大会
会议内容 ▼▲
- 1.To elect the seven (7) director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed.
2.To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (the “2016 Plan”), to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,500,000 common shares.
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Management Proxy Circular and Proxy Statement (commonly referred to as a “Say on Pay” vote).
4.To approve the appointment of Ernst & Young LLP (“EY”) as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
5.To receive our audited consolidated financial statements for the year ended December 31, 2023, and the report of the independent registered public accounting firm thereon.
6.To transact such other business as may properly come before the Annual Meeting, or at any adjournments or postponements thereof.
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益-0.44美元,归母净利润-7284.9万美元,同比去年增长-4.89%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.32美元,归母净利润-5353.7万美元,同比去年增长-12.65%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-0.2美元,归母净利润-3343.3万美元,同比去年增长-11.6%
|
| 2023-04-12 |
股东大会：
将于2023-05-24召开股东大会
会议内容 ▼▲
- 1.Election Of Directors. To Elect The Six (6) Director Nominees Of Arbutus Named In The Accompanying Management Proxy Circular And Proxy Statement Each To Serve Until The 2024 Annual General Meeting Of Shareholders Or Until His Qualified Successor Has Been Duly Elected Or Appointed;
2.Approval Of An Amendment To The Arbutus Biopharma Corporation 2016 Omnibus Share And Incentive Plan. To Approve An Amendment To The Arbutus Biopharma Corporation 2016 Omnibus Share And Incentive Plan, As Supplemented And Amended (The “2016 Plan”), To (A) Increase The Aggregate Number Of Common Shares Authorized For Issuance Thereunder By 3,500,000 Common Shares And (B) Increase The Aggregate Number Of Common Shares That May Be Issued Pursuant To Incentive Stock Options Granted Thereunder By 3,500,000 Common Shares;
3.Advisory Vote To Approve The Compensation Of Our Named Executive Officers. To Approve, On A Non-Binding Advisory Basis, The Compensation Of Our Named Executive Officers As Disclosed In The Accompanying Management Proxy Circular And Proxy Statement (Commonly Referred To As A “Say On Pay” Vote);
4.Ratification Of The Appointment Of The Independent Registered Public Accounting Firm. To Ratify The Appointment Of Ernst & Young Llp (“Ey”) As Our Independent Registered Public Accounting Firm For The Fiscal Year Ending December 31, 2023;
5.Receive Annual Financial Statements. To Receive Our Audited Consolidated Financial Statements For The Year Ended December 31, 2022 And The Report Of The Independent Registered Public Accounting Firm Thereon;
6.Any Other Business. To Transact Such Other Business As May Properly Come Before The Annual Meeting, Or At Any Adjournments Or Postponements Thereof.
|
| 2022-04-11 |
股东大会：
将于2022-05-25召开股东大会
会议内容 ▼▲
- 1.To elect the seven (7) director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement each to serve until the 2023 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed;
2.To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (the “2016 Plan”), to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,500,000 common shares;
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Management Proxy Circular and Proxy Statement (commonly referred to as a “Say on Pay” vote);
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
5.To receive our audited consolidated financial statements for the year ended December 31, 2021 and the report of the independent registered public accounting firm thereon;
6.To transact such other business as may properly come before the Annual Meeting, or at any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-08 |
股东大会：
将于2021-05-26召开股东大会
会议内容 ▼▲
- 1.To elect the eight (8) director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement each to serve until the 2022 Annual General Meeting of Shareholders or until his qualified successor has been duly elected or appointed;
2.To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (the “2016 Plan”), to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,000,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,000,000 common shares;
3.To approve, on a non-binding advisory basis, the compensation of our named executed officers as disclosed in the accompanying Management Proxy Circular and Proxy Statement (commonly referred to as a “Say on Pay” vote);
4.To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers (commonly referred to as a “Say on Frequency” vote);
5.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
6.To receive our audited consolidated financial statements for the year ended December 31, 2020 and the report of the independent registered public accounting firm thereon
7.To transact such other business as may properly come before the Annual Meeting, or at any adjournments or postponements thereof.
|
| 2020-04-24 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.ELECTION OF DIRECTORS. To elect the eight director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement to serve until the 2021 Annual General Meeting of Shareholders or until their qualified successors have been duly elected or appointed;
2.APPROVAL OF AN AMENDMENT TO THE ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN. To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (the "2016 Plan"), to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,000,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,000,000 common shares;
3.APPROVAL OF THE ARBUTUS BIOPHARMA CORPORATION 2020 EMPLOYEE STOCK PURCHASE PLAN. To approve the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan as more fully described in the accompanying Management Proxy Circular and Proxy Statement;
4.RATIFICATION OF THE APPOINTMENT OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. To ratify the appointment of Ernst & Young LLP as Arbutus' independent registered public accounting firm for the fiscal year ending December 31, 2020;
5.RECEIVE ANNUAL FINANCIAL STATEMENTS. To receive the audited consolidated financial statements of Arbutus for the year ended December 31, 2019 and the report of the independent registered public accounting firm thereon;
6.ANY OTHER BUSINESS. To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.
|
| 2019-04-23 |
股东大会：
将于2019-05-22召开股东大会
会议内容 ▼▲
- 1.RECEIVE ANNUAL FINANCIAL STATEMENTS. To receive the audited consolidated financial statements of Arbutus for the year ended December 31, 2018 and the report of the independent registered public accounting firm thereon;
2.ELECTION OF DIRECTORS. To elect the seven director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement to serve until the 2020 Annual General Meeting of Shareholders or until their qualified successors have been duly elected or appointed;
3.APPROVAL OF THE APPOINTMENT OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. To approve the appointment of Ernst & Young LLP as Arbutus' independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.ANY OTHER BUSINESS. To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.
|
| 2018-04-25 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- 1.RECEIVE ANNUAL FINANCIAL STATEMENTS. To receive the audited consolidated financial statements of Arbutus for the year ended December 31, 2017 and the report of the independent auditor thereon;
2.ELECTION OF DIRECTORS. To elect the seven director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement to serve until the 2019 Annual General Meeting of the Shareholders or until their qualified successors have been duly elected or appointed;
3.RATIFICATION OF THE APPOINTMENT OF THE INDEPENDENT AUDITOR. To ratify the appointment of KPMG LLP as our independent auditor for the fiscal year ended December 31, 2018;
4.ADVISORY VOTE TO APPROVE COMPENSATION OF NAMED EXECUTIVE OFFICERS. To approve, on an advisory basis, Arbutus's named executive officer compensation;
5.ANY OTHER BUSINESS. To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.
|
| 2017-12-06 |
股东大会：
将于2018-01-11召开股东大会
会议内容 ▼▲
- 1.To approve the issuance by the Company to Roivant Sciences Ltd. (“Roivant”) of a second tranche of 664,000 series A participating convertible preferred shares of the Company (the “Preferred Shares”) at a price of $100 per share for gross proceeds to the Company of $66.4 million (the “Second Tranche”), and common shares, no par value, issuable upon conversion of the Preferred Shares, pursuant to the Subscription Agreement between the Company and Roivant dated October 2, 2017 (the “Subscription Agreement”), as part of a larger subscription by Roivant under the Subscription Agreement for an aggregate of 1,164,000 Preferred Shares for gross proceeds to the Company of $116.4 million (the “Private Placement”).
2.To approve an amendment to Part 27 of Arbutus’ Articles of Incorporation (“Articles”) to extend the period during which certain decisions of the Board of Directors of the Company (the "Board") require approval of at least 70% of the directors from March 4, 2018 to October 16, 2021.
3.To approve an amendment to Part 28 of Arbutus’ Articles pursuant to which: (i) Roivant would have the right until October 16, 2021, subject to certain conditions, to nominate up to three members of the Board (at least one of whom must be "independent" within the meaning of the Articles, if Roivant has three nominees), and (ii) for so long as Roivant has such nomination rights, the total number of directors of Arbutus would not, without the prior written consent of Roivant, be permitted to exceed seven directors, the majority of whom would be required to be "independent".
4.To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.
|
| 2017-04-18 |
股东大会：
将于2017-05-24召开股东大会
会议内容 ▼▲
- 1.RECEIVE ANNUAL FINANCIAL STATEMENTS. To receive the audited consolidated financial statements of Arbutus for the year ended December 31, 2016 and the report of the independent auditor thereon;
2.ELECTION OF DIRECTORS. To elect the eight director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement to serve until the 2018 Annual General Meeting of the Shareholders or until their qualified successors have been duly elected or appointed;
3.RATIFICATION OF THE APPOINTMENT OF THE INDEPENDENT AUDITOR. To ratify the appointment of KPMG LLP as our independent auditor for the fiscal year ended December 31, 2017;
4.ANY OTHER BUSINESS. To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.
|
| 2016-04-08 |
股东大会：
将于2016-05-19召开股东大会
会议内容 ▼▲
- 1. RECEIVE ANNUAL FINANCIAL STATEMENTS. To receive the audited consolidated financial statements of Arbutus for the year ended December 31, 2015 and the report of the independent auditor thereon;
2. ELECTION OF DIRECTORS. To elect the seven directors of Arbutus named in the accompanying Management Proxy Circular on Proxy Statement to serve until the 2017 annual general meeting of the Shareholders or until their successors have been duly elected and qualified;
3. RATIFICATION OF THE APPOINTMENT OF THE INDEPENDENT AUDITOR. To ratify the appointment of KPMG LLP as our independent auditor for the fiscal year ended December 31, 2016;
4. APPROVAL OF AMENDMENTS TO THE ARBUTUS 2011 OMNIBUS SHARE COMPENSATION PLAN. To approve certain amendments to the 2011 Omnibus Share Compensation Plan as more fully described in the accompanying Management Proxy Circular and Proxy Statement;
5. APPROVAL OF THE 2016 OMNIBUS SHARE AND INCENTIVE PLAN. To approve the 2016 Omnibus Share and Incentive Plan and reserve for issuance 5,000,000 common shares thereunder;
6. ANY OTHER BUSINESS. To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.
|
| 2015-05-29 |
股东大会：
将于2015-07-09召开股东大会
会议内容 ▼▲
- 1.To receive the audited consolidated financial statements of Tekmira for the year ended December 31, 2014 and the report of the independent auditor thereon;
2.To elect the seven directors of Tekmira named in the attached proxy statement to serve until the 2016 annual general meeting of the Shareholders or until their successors have been duly elected and qualified;
3.To re-appoint KPMG LLP as our independent auditor to hold office for the ensuing year;
4.To consider, and if thought advisable, approve an ordinary resolution authorizing an amendment of Tekmira’s omnibus share compensation plan to increase, by 3,500,000 common shares, the number of common shares in respect of which awards may be granted thereunder;
5.To approve an amendment to Tekmira’s Articles to set the quorum for the transaction of business at a meeting of Shareholders as the presence, in person or by proxy, of the holders of at least 33 1/3% of the Common Shares of Tekmira;
6.To approve, on an advisory basis, Tekmira’s named executive officer compensation;
7.To approve, on an advisory basis, that the non-binding advisory vote on named executive officer compensation should occur every 1, 2, or 3 years;
8.To transact such other business as may properly come before the Meeting, or at any adjournments or postponements thereof.
|